Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Uridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.90 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.90 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.90 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.90 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.74 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.69 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.68 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL157643 | 1.00 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL30094506 | 1.00 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL29801499 | 1.00 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL28065954 | 1.00 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL376208 | 1.00 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL28131489 | 0.99 | SLC28A1 (0.88) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL17074124 | 0.99 | SLC28A1 (0.88) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2370972 | 0.99 | SLC28A1 (0.88) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL17439380 | 0.95 | SLC28A1 (0.85) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL5330850 | 0.95 | SLC28A1 (0.85) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7495 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260117271-A1 | SPECTRAL MONITORING OF IN VITRO TRANSCRIPTION | SANOFI PASTEUR INC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260028622-A1 | RNA NANOSTRUCTURES WITH BASE MODIFICATIONS FOR REDUCING INNATE IMMUNOGENICITY | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2026-01-29 | — | — | US | claimed |
| US-20250388944-A1 | IN VITRO TRANSCRIPTION TECHNOLOGIES | BioNTech SE (DE) | 2025-12-25 | — | — | US | claimed |
| US-20250378906-A1 | METHODS AND ARRANGEMENTS FOR INTERACTIVE SIMULATION OF XRNA PRODUCTION | ARRANTA BIO HOLDINGS LLC (US) | 2025-12-11 | — | — | US | claimed |
| US-20250369028-A1 | CONTINUOUS IN VITRO TRANSCRIPTION PROCESS AND APPARATUS | MODERNATX, INC. (US) | 2025-12-04 | — | — | US | claimed |
| US-12460259-B2 | Fed-batch in vitro transcription process | MODERNATX, INC. (US) | 2025-11-04 | — | — | US | claimed |
| US-20250277180-A1 | APPARATUS, SYSTEMS AND METHODS FOR CONTINUOUS RNA MANUFACTURING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-09-04 | — | — | US | claimed |
| EP-4599077-A1 | SPECTRAL MONITORING OF IN VITRO TRANSCRIPTION | Sanofi Pasteur Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| CN-120189502-A | Mycobacterium tuberculosis antigen combination, mRNA encoding the same and vaccine | 复旦大学 | 2025-06-24 | — | — | CN | claimed |
| US-5565327-A | DETECTING HYPERPHOSPHORYLATION OF KINASE SUBSTRATE | DUKE UNIVERSITY (US) | 1996-10-15 | — | — | US | claimed |
| US-5547835-A | USING THE SANGER SEQUENCING STRATEGY AND ASSEMBLING THE SEQUENCE INFORMATION BY ANALYSIS OF THE NESTED FRAGMENTS OBTAINED BY BASE-SPECIFIC CHAIN TERMINATION VIA THEIR DIFFERENT MOLECULAR MASSES | SEQUENOM, INC. (US) | 1996-08-20 | — | — | US | claimed |
| EP-0679196-A1 | DNA SEQUENCING BY MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1995-11-02 | — | — | EP | claimed |
| WO-1995026136-A1 | PARASITE ENZYME INHIBITORS AND SUBSTRATE ANALOGS | DUKE UNIVERSITY (US) | 1995-10-05 | — | — | WO | claimed |
| WO-1994016101-A2 | DNA SEQUENCING BY MASS SPECTROMETRY | KOESTER HUBERT (US) | 1994-07-21 | — | — | WO | claimed |
| EP-0519053-A4 | NUCLEIC ACID AMPLIFICATION WITH DNA-DEPENDENT RNA POLYMERASE ACTIVITY OF RNA REPLICASES | — | 1993-03-31 | — | — | EP | claimed |
| EP-0519053-A1 | NUCLEIC ACID AMPLIFICATION WITH DNA-DEPENDENT RNA POLYMERASE ACTIVITY OF RNA REPLICASES. | PROMEGA CORP (US) | 1992-12-23 | — | — | EP | claimed |
| WO-1992012261-A1 | NUCLEIC ACID AMPLIFICATION WITH DNA-DEPENDENT RNA POLYMERASE ACTIVITY OF RNA REPLICASES | PROMEGA CORPORATION (US) | 1992-07-23 | — | — | WO | claimed |
| EP-0076647-A2 | Culture media for cells originating from the immune system | HANA Biologics Incorporated (US) | 1983-04-13 | — | — | EP | claimed |
| EP-0009076-B1 | METHOD FOR THE QUANTITATIVE ENZYMATIC DETERMINATION OF ADP AND REAGENT FOR THIS METHOD | Roche Diagnostics GmbH (DE) | 1981-07-29 | — | — | EP | claimed |